HelbertRondon-Berrios University of Pittsburgh School of MedicineUnited States

HelbertRondon-Berrios
Dr. Rondon-Berrios is a Professor of Medicine in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine where he also serve as the Program Director of the Nephrology Fellowship Training Program. Dr. Rondon-Berrios obtained his MD degree at Universidad Nacional Mayor de San Marcos in Lima, Peru. He then completed Internal Medicine Residency training at University of Texas Medical Branch in Galveston, Texas followed by Nephrology Fellowship at University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania where he also received a Master of Science degree in medical education. Dr. Rondon-Berrios has authored several publications in the area of hyponatremia. He had received NIH funding to study the role of oral urea in the management of chronic hyponatremia. His current research focus on the efficacy and safety profile of desmopressin to prevent rapid correction of hyponatremia, and the neurological outcomes of profound hyponatremia (plasma sodium < 110 mmol/L).
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Precise Phenotyping and Treatment
HeatherReich Chairperson University of Toronto, University Health NetworkCanada
SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comSanatorio Parque SAArgentina
  • Deciphering the IGAN Cell Atlas
    JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deHeidelberg UniversityGermany
  • Complement-mediated Kidney Diseases in the Era of Complement Inhibitors
    MarinaVivarelli Speaker marina.vivarelli@opbg.netLaboratory of Nephrology, Bambino Gesù Children's HospitalItaly
  • CART-T
    JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio
  • New Targets to Reduce the Burden of Rare Kidney Diseases
    LauraMariani Speaker University of MichiganUnited States
  • Q and A
Hall C4
11 a.m.
12 p.m.
Plenary Session 2: CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? (Obiageli Eunice Nnodu, Nigeria)
AgnesFogo Chairperson United States
GuillermoRosa Diez Chairperson guillermo.rosadiez@hospitalitaliano.org.arHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of NephrologyArgentina
  • My Story
    VictoriaGray Speaker vwright_03@yahoo.comUnited States
  • CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? Hugh de Wardener Lecture
    Obiageli EuniceNnodu Speaker oennodu@gmail.comUniversity of AbujaNigeria
Hall A
12:15 p.m.
1:15 p.m.
Hot Debate: Should a Low Protein Diet (+/- Ketoanalogue Supplementation) Be Part of Advanced CKD Management?
CarlaAvesani Chairperson carla.avesani@ki.seKarolinska InstituteSweden
SahirKalim Chairperson skalim@mgh.harvard.eduHarvard Medical School/ Massachusetts General Hospital United States
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - PROS
    ConnieRhee Speaker crhee@mednet.ucla.eduUCLAUnited States
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - CONS
    SwapnilHiremath Speaker University of OttawaCanada
Hall A
3 p.m.
4 p.m.
A Balancing Act: Your Kidneys and Electrolytes
Angela Yee-MoonWang Chairperson Hong Kong/SingaporeSingapore
ThiagoDe Azevedo Reis Chairperson thiagoreisnefro@gmail.comHospital Sírio-Libanês, São Paulo, Brazil & Fenix Brazil
  • Is Magnesium a Missing Puzzle for Vascular Calcification in CKD?
    SolaAoun Bahous Speaker sola.bahous@gmail.comLebanese American University School of MedicineLebanon
  • Should Potassium Be Restricted or Not in CKD?
    RobertoPecoits Filho Speaker Arbor Research Collaborative for HealthUnited States
  • Metabolic Acidosis in CKD: When to Treat? What to Target?
    MitchellRosner Speaker Univeristy of Virginia HealthUnited States
  • Q and A
Hall A
Cardiorenal Syndrome: Updates in the Pathophysiology and State-of-the-Art Treatment
FelipeInserra Chairperson felipe.inserra@gmail.comArgentina
YelenaDrexler Chairperson yrd6@miami.eduUniversity of Miami Miller School of MedicineUnited States
  • New Insights into the Mechanisms of Kidney Injury in the CRS
    WendyMccallum Speaker wmccallum@tuftsmedicalcenter.orgUnited States
  • Novel Pharmacological Treatments of the CRS
    MarkSarnak Speaker msarnak@tuftsmedicalcenter.orgTufts Medical CenterUnited States
  • Device-related Treatment for CRS
    ClaudioRonco Speaker cronco@goldnet.itInternational Renal Research Institute of VicenzaItaly
  • Q and A
Hall D
4:30 p.m.
5:30 p.m.
Building Competency in Nephrology Education
Augusto CesarSoares dos Santos Junior Chairperson acssjunior@hotmail.comHospital das Clinicas, UFMG; Fac Ciências MedicasBrazil
Li-LiHsiao Chairperson lhsiao@bwh.harvard.eduBrigham and Women\'s Hospital, Harvard Medical SchoolUnited States
  • Curriculum Design to Developing Competency in Nephrology Practice
    ReneScalet Dos Santos Neto Speaker renesantosneto@gmail.comFaculdades Pequeno Principe (FPP) - BrazilBrazil
  • Developing Clinical Reasoning
    KarenWarburton Speaker KMW2G@uvahealth.orgUniversity of Virginia Health SystemUnited States
  • Assessment of Nephrology Trainees to Ensure Competence
    SolaAoun Bahous Speaker sola.bahous@gmail.comLebanese American University School of MedicineLebanon
  • Q and A
Hall C2
Salt Substitutes and HTN/CVD
ConnieRhee Chairperson crhee@mednet.ucla.eduUCLAUnited States
GerardoGamba Chairperson gamba@biomedicas.unam.mxUniversidad Nacional Autónoma de MéxicoMexico
  • Potassium-based Salt Substitutes and CVD
    HoornEwout Speaker e.j.hoorn@erasmusmc.nlErasmus Medical Center, Rotterdam, The NetherlandsNetherlands
  • Strategies for Scaling the Use of Potassium-enriched Salt
    BruceNeal Speaker lclifford@georgeinstitute.org.auThe George Institute, UNSW, Imperial CollegeAustralia
  • Use of Salt Meters to Reduce Salt Intake
    SurasakKantachuvesiri Speaker surasak.kan@mahidol.ac.thNephrology Division, Faculty of Medicine, RamathibThailand
  • Q and A
Hall E

Day 2 - Monday April 15, 2024

Time Session
3 p.m.
4 p.m.
Treatment Goals for Severe Hyponatremia: A Debate on Current Guidelines Program
MitchellRosner Chairperson Univeristy of Virginia HealthUnited States
  • Overview of Hyponatremia
    Angela Yee-MoonWang Speaker Hong Kong/SingaporeSingapore
  • Pro: Current Guidelines are Appropriate
    HelbertRondon-Berrios Speaker rondonberriosh@upmc.eduUniversity of Pittsburgh School of MedicineUnited States
  • Con: Current Guidelines are Too Conservative
    CarlosAyus Speaker carlosayus@yahoo.comUniversity of California IrvineUnited States
  • Discussion
Hall C3
3:45 p.m.
4:45 p.m.
Young Nephrologists Quiz-a-Thon
MarinaWainstein Spotlight Chairperson marinawainstein@outlook.comUniversity of QueenslandAustralia
Spotlight Stage 1 (exhibition hall)

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10 a.m.
Type 2 Diabetes in Kidney Disease: Recent Updates and Best Practices for Detection and Treatment
DebasishBanerjee Chairperson dbanerje@sgul.ac.ukSt George's University Hospital NHS Foundation TrUnited Kingdom
MegJardine Chairperson NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • Setting the Scene
    MegJardine Speaker NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • DM and CKD: Which Treatment Should I Use for Different Populations?
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • How to Design Studies on Answering Unanswered Questions
    VladoPerkovic Speaker vlado.perkovic@unsw.edu.auUniversity of New South Wales, Sydney, AustraliaAustralia
  • The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes
    DavidWheeler Speaker University College LondonUnited Kingdom
  • Q and A
Hall C4
Hi Aldo, What's New? Advances in Aldosterone in Health and Disease
CarlosSchreck Chairperson carlos.schreck@gmail.comHospital Italiano de Buenos Aires- NephrologyArgentina
KellyHaughton Chairperson kidneydoctorpanama@gmail.comSLANH, PanamaPanama
  • Why Are Fewer Than I% Of Hypertensive Patients Ever Screened For Primary Aldosteronism?
    John Funder Speaker John.Funder@hudson.org.auThe Hudson Institute of Medical Research Clayton 3168 Victoria Australia; Monash University, Clayton 3600 Victoria AustraliaAustralia
  • Aldosterone and Disease
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUniversity of PennsylvaniaUnited States
  • New Trials Using Aldosterone Synthese Blockade
    MichelAzizi Speaker michel.azizi@aphp.frUniversité Paris Cité, Hypertension department, HôFrance
  • Targeting MR for Heart and Kidney Protection
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall E
9 a.m.
10:30 a.m.
Clinical Management of Glomerulonephritis (GN)
Juan ManuelMejia Vilet Chairperson jmmejia@hotmail.comInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico
ValeriaAlberton Chairperson vgalberton@gmail.comHospital Fernandez/ Hospital El CruceArgentina
  • Updates on IgAN Management
    HernánTrimarchi Speaker HOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
  • Membranous GN Classification and Management
    PierreRonco Speaker Hôpital TenonFrance
  • MPGN Updates
    SanjeevSethi Speaker Mayo ClinicUnited States
  • Managing Vasculitis
    RobertaFenoglio Speaker roberta.fenoglio@unito.itOspedale San Giovanni BoscoItaly
  • Q and A
Hall A
11 a.m.
12:15 p.m.
Plenary Session 4: Insights into SGLT2 Inhibitors: A Story of Discovery (Ele Ferrannini, Italy)
AlessiaFornoni Chairperson United States
Prof LizLightstone Chairperson Imperial College LondonUnited Kingdom
MasaomiNangaku Chairperson mnangaku@m.u-tokyo.ac.jpJapan
  • Acceptance Speech: Bywaters Award
    MotokoYanagita Speaker Kyoto UniversityJapan
  • Insights into SGLT2 Inhibitors: A Story of Discovery. Donald Seldin Lecture
    EleFerrannini Speaker eleferrannini@gmail.comUniversity of PisaItaly
  • ELP2 Graduation
    MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan
Hall A
12:30 p.m.
1:30 p.m.
Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120?
MarceloOrías Chairperson marcelo.orias@gmail.comArgentina
MarkSarnak Chairperson msarnak@tuftsmedicalcenter.orgTufts Medical CenterUnited States
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - PROS
    TaraChang Speaker tichang@stanford.eduStanford UniversityUnited States
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - CONS
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUniversity of PennsylvaniaUnited States
Hall A

Pre-Congress - Saturday April 13, 2024

Time Session
4:30 p.m.
6 p.m.
WCN'24 Opening Ceremony and Plenary Session 1: The Origin of the Universe (Daniel de Florian, Argentina)
  • ISN President's Address
    MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan
  • Tribute to Stewart Cameron
  • Welcome by WHO Director of Non-Communicable Diseases Dr Bente Mikkelsen
  • Welcome by Dr. Marina Papaginovic, SAN President; Dr. Guillermo Rosa Diez, WCN Local Organising Group Chair; and Dr. Jorge Rico, SLANH President and WCN Local Organizing Group co-Chair
    GuillermoRosa Diez Speaker guillermo.rosadiez@hospitalitaliano.org.arHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of NephrologyArgentina
    JorgeRico Speaker jorgericof@yahoo.comColombia
    MariaPapaginovic Leiva Speaker drapapaginovicleiva@gmail.comArgentina
  • Welcome by Minister of Health for Buenos Aries Dr Fern
  • Welcome by SPWG Chair Alessia Fornoni
    AlessiaFornoni Speaker United States
  • The Origin of the Universe
    DanielDe Florian Speaker deflo@unsam.edu.arUniversidad Nacional de San MartinArgentina
  • Acceptance Speech: Hamburger Award
    AdeeraLevin Speaker University of British Columbia and Providence Health CareCanada
Hall A